Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:CRMDNYSE:IKTNASDAQ:IMNM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.50+7.0%$3.34$2.30▼$4.73$663.22M1.931.06 million shs1.44 million shsCRMDCorMedix$6.74+0.4%$10.43$3.61▼$13.85$408.96M1.53986,539 shs2.20 million shsIKTInhibikase Therapeutics$2.29-3.4%$2.42$1.12▼$4.20$158.84M1.04224,020 shs104,788 shsIMNMImmunome$6.99-4.0%$9.50$6.90▼$24.87$607.79M1.93854,933 shs1.06 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+6.71%+3.86%+9.03%+34.62%CRMDCorMedix0.00%-38.22%-34.24%-17.90%+62.02%IKTInhibikase Therapeutics0.00%-3.38%-2.14%-24.92%-0.43%IMNMImmunome0.00%-14.55%-21.37%-33.68%-72.61%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma1.412 of 5 stars3.50.00.00.02.00.80.6CRMDCorMedix2.6038 of 5 stars4.61.00.00.03.10.00.6IKTInhibikase Therapeutics1.313 of 5 stars3.30.00.00.01.70.00.6IMNMImmunome2.1144 of 5 stars3.51.00.00.03.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5057.14% UpsideCRMDCorMedix 3.13Buy$15.14124.67% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50183.84% UpsideIMNMImmunome 3.00Buy$25.50264.81% UpsideCurrent Analyst Ratings BreakdownLatest IKT, CRMD, IMNM, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.003/25/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/11/2025IMNMImmunomeLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.003/10/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.003/7/2025CRMDCorMedixLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M107.47N/AN/A$0.63 per share5.56CRMDCorMedix$43.47M9.41N/AN/A$1.28 per share5.27IKTInhibikase Therapeutics$260K610.92N/AN/A$1.78 per share1.29IMNMImmunome$9.04M67.23N/AN/A$2.77 per share2.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/1/2025 (Estimated)CRMDCorMedix-$46.34M-$0.33N/A7.17N/AN/A-79.21%-64.68%5/8/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIMNMImmunome-$106.81M-$5.17N/AN/AN/A-3,014.59%-48.63%-41.62%5/13/2025 (Estimated)Latest IKT, CRMD, IMNM, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 million3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02CRMDCorMedixN/A3.963.60IKTInhibikase TherapeuticsN/A0.850.85IMNMImmunomeN/A6.176.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%CRMDCorMedix34.18%IKTInhibikase Therapeutics3.81%IMNMImmunome44.58%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma4.00%CRMDCorMedix5.20%IKTInhibikase Therapeutics4.59%IMNMImmunome8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90189.49 million181.91 millionOptionableCRMDCorMedix3060.68 million57.52 millionOptionableIKTInhibikase Therapeutics669.36 million66.18 millionNot OptionableIMNMImmunome4086.95 million72.92 millionOptionableIKT, CRMD, IMNM, and ABUS HeadlinesRecent News About These CompaniesImmunome (NASDAQ:IMNM) Shares Up 4.4% on Insider Buying ActivityMarch 28 at 10:26 AM | marketbeat.comImmunome (NASDAQ:IMNM) Trading Up 4.4% After Insider Buying ActivityMarch 28 at 2:11 AM | americanbankingnews.comImmunome CEO buys $999.5K in common stockMarch 28 at 1:59 AM | markets.businessinsider.comClay B. Siegall Buys 137,100 Shares of Immunome, Inc. (NASDAQ:IMNM) StockMarch 27 at 4:51 PM | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up Following Insider Buying ActivityMarch 27 at 10:27 AM | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 137,100 Shares of StockMarch 27 at 6:00 AM | insidertrades.comImmunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying ActivityMarch 27 at 1:39 AM | americanbankingnews.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Acquires 7,000 Shares of StockMarch 26, 2025 | marketbeat.comPhilip Tsai Buys 12,300 Shares of Immunome, Inc. (NASDAQ:IMNM) StockMarch 26, 2025 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 7,000 Shares of StockMarch 26, 2025 | insidertrades.comVirtu Financial LLC Makes New $486,000 Investment in Immunome, Inc. (NASDAQ:IMNM)March 26, 2025 | marketbeat.comImmunome CTO buys $103.6K in common stockMarch 26, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Reaches New 52-Week Low - Should You Sell?March 25, 2025 | marketbeat.comImmunome (IMNM) to Release Quarterly Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comWedbush Comments on Immunome's Q1 Earnings (NASDAQ:IMNM)March 25, 2025 | americanbankingnews.comWedbush Has Positive Estimate for Immunome Q1 EarningsMarch 24, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Price Target Cut to $25.00 by Analysts at GuggenheimMarch 23, 2025 | americanbankingnews.comImmunome (NASDAQ:IMNM) Receives Overweight Rating from StephensMarch 22, 2025 | americanbankingnews.comWedbush Keeps Their Buy Rating on Immunome (IMNM)March 21, 2025 | markets.businessinsider.comImmunome (IMNM) Receives a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Receives "Outperform" Rating from WedbushMarch 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Archer Aviation Stock Climbs as Midnight eVTOL Nears RealityBy Jeffrey Neal Johnson | March 10, 2025View Archer Aviation Stock Climbs as Midnight eVTOL Nears RealityCan TikTok Stock Picks Really Make You Rich?By Dan Schmidt | March 17, 2025View Can TikTok Stock Picks Really Make You Rich?IKT, CRMD, IMNM, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.50 +0.23 (+7.03%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.48 -0.02 (-0.57%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.CorMedix NASDAQ:CRMD$6.74 +0.03 (+0.45%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$6.74 +0.00 (+0.07%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Inhibikase Therapeutics NYSE:IKT$2.29 -0.08 (-3.38%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.31 +0.02 (+0.83%) As of 03/28/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Immunome NASDAQ:IMNM$6.99 -0.29 (-3.98%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$7.08 +0.09 (+1.22%) As of 03/28/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
